Goldman Sachs’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-642,652
| Closed | -$9.61M | – | 6511 |
|
|
2022
Q4 | $9.61M | Buy |
642,652
+584,788
| +1,011% | +$8.1M | ﹤0.01% | 2625 |
|
|
2022
Q3 | $476K | Buy |
57,864
+36,797
| +175% | +$283K | ﹤0.01% | 5020 |
|
|
2022
Q2 | $138K | Buy |
21,067
+5,889
| +39% | +$28.5K | ﹤0.01% | 5761 |
|
|
2022
Q1 | $85K | Sell |
15,178
-242,930
| -94% | -$1M | ﹤0.01% | 6155 |
|
|
2021
Q4 | $1.21M | Sell |
258,108
-23,559
| -8% | -$146K | ﹤0.01% | 4682 |
|
|
2021
Q3 | $1.74M | Sell |
281,667
-61,175
| -18% | -$366K | ﹤0.01% | 4319 |
|
|
2021
Q2 | $2.26M | Buy |
342,842
+299,239
| +686% | +$2.06M | ﹤0.01% | 4092 |
|
|
2021
Q1 | $319K | Buy |
43,603
+1,523
| +4% | +$13.1K | ﹤0.01% | 5400 |
|
|
2020
Q4 | $243K | Sell |
42,080
-69,527
| -62% | -$398K | ﹤0.01% | 4991 |
|
|
2020
Q3 | $663K | Buy |
111,607
+39,038
| +54% | +$193K | ﹤0.01% | 4325 |
|
|
2020
Q2 | $374K | Buy |
+72,569
| New | +$458K | ﹤0.01% | 4522 |
|
|
2020
Q1 | – | Sell |
-4,488
| Closed | -$28K | – | 5728 |
|
|
2019
Q4 | $28K | Sell |
4,488
-3,290
| -42% | -$24.2K | ﹤0.01% | 5154 |
|
|
2019
Q3 | $65K | Sell |
7,778
-27,279
| -78% | -$203K | ﹤0.01% | 5017 |
|
|
2019
Q2 | $236K | Buy |
35,057
+32,248
| +1,148% | +$276K | ﹤0.01% | 4718 |
|
|
2019
Q1 | $23K | Sell |
2,809
-5,355
| -66% | -$55.3K | ﹤0.01% | 5046 |
|
|
2018
Q4 | $131K | Buy |
8,164
+1,202
| +17% | +$26.4K | ﹤0.01% | 4948 |
|
|
2018
Q3 | $231K | Buy |
6,962
+4,993
| +254% | +$128K | ﹤0.01% | 4845 |
|
|
2018
Q2 | $44K | Sell |
1,969
-76,264
| -97% | -$1.81M | ﹤0.01% | 5385 |
|
|
2018
Q1 | $2.27M | Buy |
78,233
+54,139
| +225% | +$1.58M | ﹤0.01% | 3514 |
|
|
2017
Q4 | $672K | Buy |
+24,094
| New | +$748K | ﹤0.01% | 4594 |
|
|
2017
Q3 | – | Sell |
-1,373
| Closed | -$30K | – | 6984 |
|
|
2017
Q2 | $30K | Buy |
+1,373
| New | +$10.8K | ﹤0.01% | 6476 |
|
|
2016
Q4 | – | Sell |
-1,693
| Closed | -$15K | – | 7195 |
|
|
2016
Q3 | $15K | Buy |
+1,693
| New | +$15.9K | ﹤0.01% | 6821 |
|
|
2016
Q1 | – | Sell |
-1,900
| Closed | -$24K | – | 7440 |
|
|
2015
Q4 | $24K | Sell |
1,900
-5,595
| -75% | -$66.5K | ﹤0.01% | 6805 |
|
|
2015
Q3 | $91K | Buy |
7,495
+596
| +9% | +$8.61K | ﹤0.01% | 6542 |
|
|
2015
Q2 | $120K | Sell |
6,899
-11,885
| -63% | -$214K | ﹤0.01% | 6522 |
|
|
2015
Q1 | $272K | Buy |
18,784
+4,963
| +36% | +$54.2K | ﹤0.01% | 5738 |
|
|
2014
Q4 | $116K | Sell |
13,821
-5,689
| -29% | -$52K | ﹤0.01% | 6516 |
|
|
2014
Q3 | $217K | Buy |
19,510
+5
| +0% | +$64 | ﹤0.01% | 6085 |
|
|
2014
Q2 | $357K | Sell |
19,505
-2,533
| -11% | -$32.9K | ﹤0.01% | 5632 |
|
|
2014
Q1 | $329K | Sell |
22,038
-2,407
| -10% | -$43.2K | ﹤0.01% | 5662 |
|
|
2013
Q4 | $447K | Buy |
24,445
+11,066
| +83% | +$222K | ﹤0.01% | 5381 |
|
|
2013
Q3 | $275K | Buy |
13,379
+4,685
| +54% | +$107K | ﹤0.01% | 5629 |
|
|
2013
Q2 | $217K | Buy |
+8,694
| New | +$372K | ﹤0.01% | 5535 |
|
Goldman Sachs's AVEO Position: Q1 2023 in Review
Goldman Sachs sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 642,652 shares — an estimated $9.61M sold.
Goldman Sachs first reported a position in AVEO in Q2 2013 and held it in 33 quarters. The position peaked at $9.61M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Goldman Sachs reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Goldman Sachs sold 642,652 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $9.61M.
- Goldman Sachs first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 33 quarters.
- Goldman Sachs's AVEO Pharmaceuticals, Inc. position peaked at $9.61M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.